UK clinicians are to begin a trial using Oxford Nanopore's MinION to diagnose pneumonia, according to the Telegraph.
The tool has been applied to determine the pathogenic cause of hemorrhagic fever, and is powering a new test for respiratory disease pathogens.
The approach is based on a new approval of the BacT/ALERT Virtuo system and new indications for the firm's procalcitonin assay.
For the 40-target panel, the trial found an overall average weighted sensitivity and specificity of 90 and 99 percent, respectively.
In PLOS this week: genetic networks involved in antibiotic sensitivity, syphilis pathogen proteome, and more.
The test is an improved version of one that was approved three years ago, and runs on the firm's illumigene molecular diagnostics platform.
The firm has also begun setting up US operations as it prepares to submit for FDA approval of its MDx system and lower respiratory tract infection diagnostic.
Cepheid will create Xpert cartridge tests to detect S. aureus and P. aeuginosa, to be used in clinical trials for biologics intended to prevent pneumonia.
A University of Alabama, Birmingham team used the Illumina MiSeq platform to perform next-generation sequencing on 15 strains of M. pneumoniae.
Meanwhile, the company is moving ahead with a clinical trial to support the assay's approval in the US.
Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.
By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.
Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.
In Nature this week: a Danish reference genome, and more.